Autopsy report · NCT00626548
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
Cause of deathFutility
“early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely to meet its primary efficacy endpoints”
Life of this trial
- Ran for about 3 years 4 months before it stopped.
- 2,577 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Conditions
- Prostate Cancer
- Interventions
- ZD4054; Palcebo
- Participants
- 2,577
- Sites
- 322
- Countries
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Finland and more
Trials that died the same way
- Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
“The primary efficacy endpoint was not met” - GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
“The study was terminated following assessment of the lack of efficacy of the study product by the Independent Data monitoring Committee for the study.” - A Pilot Study of Candesartan as a Treatment for Cocaine Dependence
“Results of interim efficacy analysis showed results were not promising.” - Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
“The study was terminated based on review of Phase 2 efficacy data” - LBH589 in Refractory Myelodysplastic Syndromes (MDS)
“Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.